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Abstract
Background: Although consumption of various plant sterol (PS)-enriched beverages is effective
in lowering plasma cholesterol, the lipid-lowering potential of PS in a soymilk format has not been
investigated thoroughly. Therefore, to evaluate the efficacy of PS-enriched soy beverages on plasma
lipids and cholesterol kinetics, we conducted two separate 28 d dietary controlled cross-over
studies. In study 1, the cholesterol-lowering efficacy of a low-fat (2 g/serving) PS enriched soy
beverage was examined in 33 normal cholesterolemic subjects in comparison with 1% dairy milk.
In study 2, we investigated the efficacy of a moderate-fat (3.5 g/serving) PS-enriched soy beverage
on plasma cholesterol concentrations and cholesterol kinetic responses in 23
hypercholesterolemic subjects compared with 1% dairy milk. Both the low and moderate-fat PS-
enriched soymilk varieties provided 1.95 g PS/d. Endpoint plasma variables were analyzed by
repeated-measures ANOVA using baseline values as covariates for plasma lipid measurements.
Results: In comparison with the 1% dairy milk control, the low-fat soy beverage reduced (P < 0.05)
total and LDL-cholesterol by 10 and 13%, respectively. Consumption of the moderate-fat PS-
enriched soy beverage reduced (P < 0.05) plasma total and LDL-cholesterol by 12 and 15%
respectively. Fasting triglycerides were reduced by 9.4% following consumption of the moderate-
fat soy beverage in comparison with the 1% dairy milk. Both low and moderate-fat PS-enriched soy
varieties reduced (P < 0.05) LDL:HDL and TC:HDL ratios compared with the 1% dairy milk
control. Consumption of the moderate-fat PS-enriched soymilk reduced (P < 0.05) cholesterol
absorption by 27%, but did not alter cholesterol synthesis in comparison with 1% dairy milk.
Conclusion: We conclude that, compared to 1% dairy milk, consumption of low and moderate-
fat PS-enriched soy beverages represents an effective dietary strategy to reduce circulating lipid
concentrations in normal to hypercholesterolemic individuals by reducing intestinal cholesterol
absorption.
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Background
Although drug treatment is effective in the management
of dyslipidemia, diet-based monotherapies or combina-
tion dietary approaches that reduce the incidence of arte-
rial vascular diseases will be integral to sustainable health
care systems of the future [1]. Consumption of plant ster-
ols (PS), constituents found in plants that chemically
resemble cholesterol, is a well-defined dietary lipid-lower-
ing strategy with repeated demonstrations of cholesterol
reductions in human clinical investigations in the range of
8-15% [2-4]. However, it is increasingly clear that the
food/beverage format used as the PS delivery vehicle may
impact PS solubility and hence modulate intestinal cho-
lesterol absorption and the magnitude of cholesterol-low-
ering [5,6]. For instance, although cholesterol reductions
are observed following consumption of PS-fortified prod-
ucts including juice [7], margarine [8], and dressings [9],
debate continues surrounding the lipid-lowering efficacy
of low-fat vs moderate and high-fat PS-fortified products
[10,11].
Considering the substantial increase in soymilk consump-
tion in North America as an alternative to dairy milk, sev-
eral studies have compared lipid-lowering responses of
soymilk versus dairy milk [12-14]. While previous animal
model investigations suggest that combination therapy of
PS and soy protein reduces circulating cholesterol concen-
trations beyond that observed with either therapy alone
[15], only one published report has investigated soymilk
as a potential PS delivery beverage in human subjects; and
this study was conducted without the advantage of a pre-
cisely controlled feeding design [16]. Furthermore, no
information is available concerning the modulation of
intestinal cholesterol absorption and synthesis in
response to PS fortified soymilk. Given the reputed health
benefits associated with the protein, isoflavone, saponin,
and fiber components of soy [17], a unique opportunity
exists to expand on these benefits through use of a PS for-
tified soy beverage. Here, we report on two separate con-
trolled clinical feeding studies evaluating the efficacy of
PS-enriched soy beverages differing in fat content on
plasma lipids in comparison to a 1% dairy milk control.
In study 1, our objective was to examine plasma lipids in
response to the consumption of a low-fat (2 g/serving) PS-
enriched soy beverage. In study 2, our objectives were to
investigate plasma lipid and cholesterol kinetic responses
following consumption of a moderate-fat (3.5 g/serving)
PS enriched soy beverage.
Results
Study 1 - Low-Fat PS-Enriched Soy Beverage
Of the forty-two subjects initially recruited for study, 33
subjects (15 males and 18 females) completed both exper-
imental phases. Nine subjects dropped out during the first
phase due to difficulties with consuming study diets (n =
2), relocation to another city (n = 1), problems with daily
centre visiting (n = 4), and personal reasons (n = 2). Pal-
atability and texture of the PS-enriched soymilk beverage
were assessed as highly acceptable. No side effects associ-
ated with soymilk or control milk consumption were
reported.
Fasting endpoint lipid concentrations in response to low-
fat PS-enriched soymilk consumption are presented in
Table 1. TC concentrations were reduced (P < 0.0001) by
10% following consumption of the low-fat PS enriched
soy beverage (203.40 ± 6.17 mg/dl; 5.26 ± 0.16 mmol/L)
in comparison with the 1% dairy milk control (224.28 ±
6.57 mg/dl; 5.80 ± 0.17 mmol/L). Plasma LDL-C concen-
trations were reduced (P < 0.0001) by 13% following low-
fat PS-enriched soymilk consumption (123.74 ± 5.80 mg/
dl; 3.20 ± 0.15 mmol/L) in comparison with the 1% dairy
milk (141.53 ± 5.80 mg/dl; 3.66 ± 0.15 mmol/L). Low-fat
PS-enriched soymilk consumption decreased (P < 0.05)
the LDL:HDL (2.74 vs 3.21) and TC:HDL (4.71 vs 5.05)
ratios relative to 1% dairy milk. No treatment effects were
observed in HDL-C and TG concentrations between the
two groups.
Further analyses of TC and LDL-C were conducted in a
subgroup (n = 14) of subjects with initial LDL-C concen-
trations above 3.4 mmol/L. Plasma TC concentrations
Table 1: Fasting plasma cholesterol concentrations in hypercholesterolemic individuals in response to the consumption of a low-fat 
and moderate-fat plant sterol-enriched soymilk and 1% dairy milk for 29 daysa
Study 1 Study 2
Plasma lipids (mg/dl) 1% Dairy Milk Low-fat Soymilk 1% Dairy Milk Moderate-fat Soymilk
Total cholesterol 224.28 ± 6.57 203.40 ± 6.19* 242.85 ± 10.44 216.16 ± 10.44†
LDL cholesterol 141.53 ± 5.80 123.74 ± 5.80* 162.41 ± 8.50 139.21 ± 7.73†
HDL cholesterol 47.17 ± 2.32 46.40 ± 2.32 47.56 ± 2.33 44.47 ± 2.71
LDL:HDL 3.21 ± 0.20 2.83 ± 0.18* 3.52 ± 0.25 3.18 ± 0.23†
Total:HDL 5.05 ± 0.26 4.71 ± 0.27* 5.38 ± 0.35 4.75 ± 0.33†
Triglycerides 178.03 ± 15.06 172.72 ± 16.83 185.12 ± 27.46 169.18 ± 25.69†
aData presented as mean ± SEM, n = 33 for study 1; n = 23 for study 2.
*, significantly different from 1% dairy milk in study 1; †, significantly different from 1% dairy milk in study 2.Lipids in Health and Disease 2009, 8:45 http://www.lipidworld.com/content/8/1/45
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decreased (P < 0.0001) by 9.5% following consumption
of the low-fat PS-enriched soymilk, as compared to con-
trols. Subjects consuming the low-fat PS-enriched soymilk
had a 12% reduction in LDL-C concentrations (P  =
0.0002), relative to the 1% dairy milk.
Study 2 - Moderate-Fat PS Enriched Soy Beverage
Of the 32 subjects initially recruited for study, 23 com-
pleted (10 males and 13 females) both experimental
phases. Of the 9 subjects who did not complete the trial,
3 dropped out during the initial days of the study citing an
inability to comply with dietary restrictions. The 6
remaining dropouts left the study following completion
of the first phase due to family (n = 2), health (n = 1), and
work-related issues (n = 3). Palatability and texture of the
PS-enriched soymilk beverage were assessed as highly
acceptable. No side effects associated with soymilk or con-
trol milk consumption were reported.
Fasting endpoint lipid concentrations in response to PS-
enriched moderate-fat soymilk consumption are pre-
sented in Table 1. TC was reduced by 12% (P < 0.0001) in
the PS-enriched soymilk group (216.16 ± 10.44 mg/dl;
5.59 ± 0.27 mmol/L) in comparison with the 1% milk
control (242.84 ± 10.44 mg/dl; 6.28 ± 0.27 mmol/L).
Subjects receiving the PS-enriched soymilk displayed a
15% reduction (P < 0.0001) in LDL-C (139.21 ± 7.73 mg/
dl; 3.60 ± 0.20 mmol/L) in comparison to 1% dairy milk
(162.41 ± 8.50 mg/dl; 4.20 ± 0.22 mmol/L). PS-enriched
soymilk consumption did not alter (P > 0.05) HDL-C con-
centrations. However, PS enriched soymilk consumption
decreased (P < 0.05) endpoint LDL:HDL (3.18 vs. 3.52)
and TC:HDL ratios (4.75 vs. 5.38) in comparison to the
1% dairy milk control. Subjects consuming the PS-
enriched soymilk displayed a 9% reduction (P = 0.02) in
plasma TG in comparison to those receiving the 1% dairy
milk control.
Cholesterol absorption, as measured by the area under the
[3,4]-13C cholesterol RBC enrichment curve, was reduced
(P = 0.02) by 27% in response to the consumption of PS-
enriched soymilk in comparison to the 1% dairy milk
control (Figure 1). In contrast, cholesterol synthesis, as
measured by deuterium incorporation, did not differ (P =
0.45) between the PS-enhanced soymilk and 1% dairy
milk groups (5.69 ± 0.63 vs 5.08 ± 0.79%/day).
Discussion
Consumption of both low and moderate-fat PS enriched
soy beverages reduced fasting total and LDL-C in compar-
ison with 1% dairy milk. Although direct statistical com-
parison between the two clinical studies is not possible,
the numerical plasma cholesterol responses between the
two studies suggest that the fat content of the soymilk had
little impact on vehicle performance as LDL-C reductions
following consumption of the low and moderate-fat
soymilk beverages were similar (13 and 15%, respec-
tively). Direct comparisons of the clinical effectiveness of
PS products between studies are often limited by differ-
ences in study design, as cholesterol reductions in
response to PS consumption are modulated by multiple
factors including background diet [18], PS dose [19] and
form [20], frequency of PS consumption [21], level and
type of fat in food vehicle [6], and baseline LDL-C concen-
tration of study subjects [18]. As the background diet and
factors pertaining to the dose, form and frequency of PS
consumption were identical between our two studies, the
comparable cholesterol-lowering response between the
soymilk beverages may help clarify confusion that exists
surrounding the effectiveness of PS enriched beverages
with differing fat content. The only minor difference
between our study protocols was the lower LDL-C base-
line concentrations of the low-fat soy beverage group
compared with the moderate-fat soymilk study subjects. It
has been suggested that subjects with higher LDL-C may
respond more favourably, and with further cholesterol
reductions, than individuals with lower LDL-C concentra-
tions [19]. However, when the analysis was conducted in
hypercholesterolemic subjects with entry LDL-C concen-
trations above 3.4 mmol/L, TC and LDL-C reductions fol-
lowing PS-enriched low-fat soymilk consumption were
similar to those reported for the entire study population.
Therefore, our results suggest that patients with lower
LDL-C concentrations may also benefit from the con-
sumption of PS enriched soymilk.
Consumption of the moderate-fat PS enriched soymilk
was associated with a 9% reduction in circulating triglyc-
erides. Although PS consumption is not traditionally asso-
ciated with modulation of triglyceride metabolism, Plat et
al. recently observed a reduction in circulating TAG by
27.5% in metabolic syndrome patients with hypertriglyc-
eridemia following the consumption of a PS yogurt drink
13C-cholesterol enrichment of red blood cells at 24, 48, 72,  and 96 h following ingestion of 75 mg of [3,4]-13C-choles- terol in response to consumption of moderate-fat plant  sterol enriched soymilk Figure 1
13C-cholesterol enrichment of red blood cells at 24, 
48, 72, and 96 h following ingestion of 75 mg of [3,4]-
13C-cholesterol in response to consumption of mod-
erate-fat plant sterol enriched soymilk. Values are 
mean ± SEM (n = 17 for soy group, 18 for dairy group).
1
3
C
-
c
h
o
l
e
s
t
e
r
o
l
 
e
n
r
i
c
h
m
e
n
t
 
o
f
 
r
e
d
 
b
l
o
o
d
 
c
e
l
l
s
 
(
0
/
0
0
)
Soy group 
AUC = 193 
Dairy group 
AUC = 255 
HoursLipids in Health and Disease 2009, 8:45 http://www.lipidworld.com/content/8/1/45
Page 4 of 7
(page number not for citation purposes)
[22]. Furthermore, this report follows a recent meta-anal-
ysis suggesting a PS-induced modulation of plasma trig-
lycerides [23], although previous meta-analyses have
failed to establish this relationship [6,19]. This PS-
induced reduction in plasma triglycerides was only
observed in subjects from study 2 who had elevated trig-
lyceride concentrations compared to study 1 subjects, giv-
ing merit to Plat's speculation that modulation of
triglycerides in response to PS consumption may be more
readily detected in study populations with high baseline
triglycerides.
It is increasingly clear that some individuals respond with
major shifts in lipid profiles to PS consumption whereas
others are much less sensitive to PS challenges. This varia-
bility of responsiveness is likely associated with single
nuclear polymorphisms (SNPs) in Niemann-Pick C1-like
1 (NPC1L1) and ATP binding cassette proteins G5
(ABCG5) and G8 (ABCG8), genes that regulate intestinal
sterol absorption and efflux [24,25]. Although the two
soymilk beverages were associated with similar LDL-C
reductions, it is clear that the low-fat soymilk study popu-
lation included more non-responders that subjects in the
moderate-fat soymilk study (Figure 2). While consump-
tion of the moderate-fat soy beverage was associated with
an LDL-C lowering ranging from from 2 to 38%, LDL-C
reductions following the low-fat soy beverage ranged
from -33 to +37%, with 9 subjects displaying increased
LDL-C following the low-fat soy treatment.
Cholesterol absorption was reduced by 27% following
consumption of the moderate-fat PS fortified soy bever-
age. The cholesterol-lowering effects of PS are related to
modulation of intestinal cholesterol absorption through
several distinct mechanisms including interference with
the micellular cholesterol incorporation [26], competi-
tion with dietary and biliary cholesterol for uptake
through the brush border NPC1L1 [27], and reduction in
cholesterol esterification and chylomicron assembly
within the intestinal enterocyte [28]. Surprisingly,
although previous investigations typically report compen-
satory increases in cholesterol synthesis in response to PS
consumption [29,30], no difference was observed in cho-
lesterol synthesis between the moderate-fat PS fortified
soy beverage and control group in the current study. The
hepatic expression of genes that regulate cholesterol syn-
thesis and plasma LDL-C trafficking, including 3-hydroxy-
3-methyl-glutaryl-CoA reductase, sterol-regulatory ele-
ment binding protein 2, and LDL-receptor, have been
shown to be transcriptionally regulated by individual pro-
tein and/or isoflavone components of soy [31,32]. There-
fore, it can be speculated that specific bioactive
components inherent in the soy beverage may have sup-
pressed the increase in cholesterol synthesis typically
observed following PS consumption. Alternatively, con-
sumption of isolated soy protein has been reported to
increase cholesterol FSR by 7.6% in hypercholesterolemic
human subjects compared with animal protein consump-
tion [33]. However, the effects of whole soymilk con-
sumption on cholesterol synthesis has not been
previously investigated.
Conclusion
Dietary approaches effective in reducing LDL-C are critical
to the development of sustainable health care systems.
Incorporation of PS into a daily dietary regimen is an
effective approach to improving dyslipidemia and poten-
tially reducing the incidence of cardiovascular diseases.
However, the food/beverage that is used to deliver an
effective PS dose is an important factor affecting the cho-
lesterol-lowering response. Results of this study suggest
that, compared with 1% dairy milk, consumption of low
and moderate-fat PS-enriched soymilk beverages are effec-
tive food based therapeutic strategies for cardiovascular
disease management through reduction of plasma lipids
and modulation of intestinal cholesterol absorption in
normal to hypercholesterolemic subjects.
Methods
Subjects
Studies were conducted at the Clinical Nutrition Research
Unit at the Richardson Centre for Functional Foods and
Nutraceuticals (RCFFN), University of Manitoba. Subjects
were recruited from the Winnipeg area using newspaper
and radio endorsements, poster advertisements, and flyer
distributions. Potential subjects, deemed eligible follow-
ing an initial phone screening, visited the RCFFN for
plasma cholesterol screening. Healthy males and females
between the ages of 19-60 y with a body mass index (BMI)
between 20-34 kg/m2 were recruited who were free of thy-
Individual % changes in LDL-C from baseline in response to  the consumption of a low and moderate-fat PS-enriched soy  beverage Figure 2
Individual % changes in LDL-C from baseline in 
response to the consumption of a low and moderate-
fat PS-enriched soy beverage.
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roid disorders, kidney disease, diabetes mellitus, and
heart disease, and were not currently taking lipid-lowering
medications. Study 1 included normal to hypercholester-
olemic subjects with a fasting plasma LDL-cholesterol
(LDL-C) between 2.1-5.2 mmol/L and TG below 2.82
mmol/L. Study 2 included hypercholesterolemic subjects
with a LDL-C greater than 3.4 mmol/L and TG below 2.82
mmol/L. Baseline characteristics of subjects who com-
pleted the study are presented in Table 2. To confirm indi-
vidual health status, all subjects underwent a complete
physical examination conducted by the study physician.
The study protocols were approved by the Bioethical
Research Ethics Board (BREB) at the University of Mani-
toba. All subjects signed informed consent to participate
in the study.
Study design and protocol
Studies were carried out as 28-d controlled feeding trials
using precisely prepared diets in a randomized crossover,
two period design. Experimental periods were separated
by a 4-wk washout period during which the subjects con-
sumed his/her habitual diets. All meals were prepared at
the Richardson Clinical Nutrition Research Unit as a 3-
day rotating menu to provide the subjects with a variety of
food during their experimental phases. Using a nutrient
composition database (Food Processor, ESHA Research,
Salem, OR), the diets were designed to contain 35% of
energy as fat, 50% as carbohydrate and 15% as protein
and meet the energy requirements of each subject using
the Mifflin equation [34]. Subjects were randomly
assigned to one of two experimental groups: the control
group receiving 1% dairy milk or the treatment group
receiving the fortified soy beverage providing 1.95 g PS/d
(PS-enriched soymilks supplied by Whitewave Foods,
Inc.) (Table 3). Enriched soy and 1% dairy milks were pro-
vided as 3 (240 ml) tetra-paks per day, 1 consumed with
each meal. To monitor compliance, subjects consumed
their daily supper meal in conjunction with one treatment
or control beverage under direct supervision. The remain-
ing meals and treatments were packed for take-out. Sub-
jects were instructed to shake the tetra paks prior to
drinking, consume only foods and beverages provided by
the clinical research team, and return the empty contain-
ers to ensure that the beverage was properly administered.
Outcome measurements
Twelve-hour fasting blood samples (26 ml) were collected
on days 1 and 2 (baseline) and 29 and 30 (endpoint) dur-
ing each phase. On day 24 of each experimental phase of
study 2 (moderate-fat soymilk study only), a fasting base-
line blood sample (0 h) was taken prior to administration
of a 75 mg oral dose of [3,4]-13C cholesterol (CDN Iso-
topes, Point-Claire, Quebec, Canada) mixed in margarine
and spread on an English muffin. Fasting blood samples
were taken on day 25 (24 h), day 26 (48 h), day 27 (72 h),
and day 28 (96 h) to measure cholesterol absorption.
Additionally, following a fasting baseline sample on day
27, an oral dose of deuterium oxide (0.7 g/kg estimated
body water) was given prior to breakfast as a tracer for
measuring fractional cholesterol synthesis.
Plasma lipids
Plasma and red blood cells (RBC) fractions were separated
by centrifugation at 3000 × g for 20 min and stored at -
80°C. Plasma total cholesterol (TC), high-density lipo-
protein cholesterol (HDL-C), and triglycerides (TG) were
determined by automated enzymatic methods on a Vitros
350 chemistry analyzer (Ortho-Clinical Diagnostics,
Markham, Ontario, Canada). LDL-C concentrations were
estimated by the difference method using the Friedewald
formula [35].
Cholesterol absorption
Cholesterol absorption was measured using the single sta-
ble isotope tracer approach with the area under the [3,4]-
13C cholesterol RBC enrichment curve over 96 h repre-
senting cholesterol absorption. Free cholesterol was
extracted from RBC according to established methods
[36]. [3,4]-13C cholesterol enrichments in RBC lipid
extracts were determined using on-line gas chromatogra-
phy/combustion/isotope ratio mass spectrometry
approach (Agilent 6890N chromatograph interfaced with
a Finnigan Delta V Pulse isotope ratio mass spectrometer
(Bremen, Germany). Isotope abundance, expressed in
delta (d) per mil (‰), was calculated using CO2 as a ref-
erence gas and further corrected against the international
reference standard, Pee Dee Belemnite limestone.
Cholesterol synthesis
Cholesterol fractional synthesis rate (FSR; %/day) was
quantified using the uptake rate of deuterium from body
water into the newly synthesized RBC free cholesterol
Table 2: Baseline characteristics of subjects who completed the 
studiesa
Study 1b Study 2c
Characteristic Mean ± SE Mean ± SE
Anthropometric measurements
Age (years) 43.00 ± 2.37 43.9 ± 0.3
Height (m) 1.68 ± 1.83 1.66 ± 0.02
Initial body weight (kg) 83.21 ± 3.37 82.8 ± 4.0
Initial BMI (kg/m2) 29.08 ± 0.97 30.0 ± 1.5
Plasma lipids (mg/dl)
Total cholesterol 210.36 ± 5.80 249.80 ± 11.60
LDL-cholesterol 129.54 ± 5.03 163.57 ± 8.12
HDL-cholesterol 47.56 ± 2.32 49.11 ± 2.70
Triglycerides 165.63 ± 15.05 206.37 ± 34.54
aData presented as mean ± SEM; n = 33 for study 1; n = 23 for study 2
bLow-fat plant sterol-enriched soymilk study
cModerate-fat plant sterol-enriched soymilk studyLipids in Health and Disease 2009, 8:45 http://www.lipidworld.com/content/8/1/45
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pool over 24 h at the end of each study period [37]. Cho-
lesterol FSR represents the fraction of the rapidly
exchangeable central free cholesterol pool that exchanges
between the plasma, liver, and intestine [38].
Statistical analyses
The sample size of 20 subjects was calculated to detect an
anticipated difference in LDL-cholesterol levels due to PS
treatment of 12% (0.54 mmol/l) using an standard devia-
tion of 0.732 mmol/l. The alpha and power were 0.05 and
0.7, respectively. All data are presented as means ± SEM.
Statistical significance was set at P < 0.05 for all analyses.
Differences in endpoint plasma variables were tested by
repeated-measures ANOVA using baseline values as cov-
ariates for plasma lipid measurements. To examine the
effect of baseline cholesterol concentrations on the lipid-
lowering efficacy of PS-enriched soymilk consumption in
study 1, further analyses of endpoint TC and LDL-C were
conducted in a subgroup (n = 14) of subjects with initial
LDL-C concentrations above 3.4 mmol/L. For cholesterol
absorption, the area under the 13C-cholesterol enrichment
curves from 24 to 96 h was calculated with the use of the
trapezoidal rule after correction for baseline values. Data
were analyzed with SPSS (version 16.0 for Mac, SPSS Inc,
Chicago, IL).
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